Whether to use GLP-1 for prediabetes is one of the most consequential questions in metabolic medicine right now. The trial data gives it a serious answer. In follow-up analyses of the STEP 1 program, participants who entered the trial with prediabetes largely returned to normal glucose regulation on semaglutide, while a substantial share of the placebo group progressed toward type 2 diabetes. Novo Nordisk has reported an 84 percent lower risk of progression over two years. We cite that figure as a company-reported post-hoc analysis and not as a pre-registered primary endpoint. The older and unambiguous evidence is that structured lifestyle change cuts progression risk by more than half. Taken together, the evidence says prediabetes is reversible and medication can help reverse it. The right answer for you depends on labs most basic panels never draw.
This guide covers what prediabetes actually is, what the GLP-1 trials show in prediabetic patients, the honest status of FDA approval, who is a candidate and who is not, and how the prescribing decision works when the fee cannot profit from the answer.
- Prediabetes means HbA1c between 5.7 and 6.4 percent, and it is a reversible stage, not a diagnosis to wait on.
- No GLP-1 is FDA-approved specifically for prediabetes; Wegovy and Zepbound are approved for weight management with weight-related conditions, Ozempic and Mounjaro for type 2 diabetes, and clinicians prescribe within those frames.
- Post-hoc analysis of STEP 1 reported roughly 84 percent lower progression from prediabetes to type 2 diabetes over two years on semaglutide, alongside lifestyle evidence from the Diabetes Prevention Program showing a 58 percent reduction.
- Weight loss itself is the mechanism: losing 5 to 10 percent of body weight measurably restores insulin sensitivity.
- The decision belongs to labs, not to marketing: HbA1c, fasting insulin, ApoB and a full panel, re-tested every 90 days.
What prediabetes is, and why waiting is the wrong default
Prediabetes is the stage where your tissues have become resistant to insulin and your pancreas is compensating by producing more of it, enough to keep your glucose mostly normal but no longer comfortably so. By the conventional definitions, an HbA1c between 5.7 and 6.4 percent, or a fasting glucose between 100 and 125 mg/dL, puts you in the range where progression to type 2 diabetes is the untreated default. The Centers for Disease Control and Prevention estimates that the large majority of adults with prediabetes do not know they have it, which tells you something about how aggressively the standard system looks for it.
The standard system's other habit is waiting. A borderline A1c gets a follow-up in a year, as if the insulin resistance driving it takes the year off in the meantime. It does not. The compensation has usually been running for years before glucose moves, and during those years it is also raising triglycerides, lowering HDL, feeding fatty liver, and making weight harder to lose. The right default is to find it early and act on it, which is exactly what a quarterly panel is for.
What the GLP-1 trials show in prediabetic patients
The evidence stack has three layers, and they fit together cleanly.
Lifestyle works, and it works first. The Diabetes Prevention Program, the landmark trial of the field, showed that structured lifestyle intervention producing modest weight loss reduced progression to type 2 diabetes by 58 percent, outperforming metformin. That finding is the foundation everything else is built on, and we treat it that way: nutrition structure, resistance training and sleep repair are the core of every prediabetes protocol we write.
GLP-1 medication adds substantial protection on top of weight loss. In the two-year extension of STEP 1, among participants who began the trial with prediabetes, the overwhelming majority on semaglutide returned to normoglycemia, while progression to diabetes continued in the placebo group; Novo Nordisk has reported the 84 percent figure from this analysis. We hedge it because post-hoc analyses rank below pre-registered endpoints, but the direction is consistent with everything else known about the drug class: GLP-1 medications improve insulin sensitivity, produce clinically meaningful weight loss, and the two effects compound.
Tirzepatide shows the same pattern, harder. In SURMOUNT 1, participants on tirzepatide saw large average weight losses, up to roughly 22.5 percent, and glycemic measures moved with the weight. Tirzepatide is also the most powerful glucose-lowering agent in the class, which is why it dominates type 2 diabetes care as Mounjaro.
The mechanism is worth understanding, because it explains the honest limits. GLP-1 medications do not fix insulin resistance directly; they reduce appetite and caloric intake, and the resulting weight loss restores insulin sensitivity. The medication is a lever on the mechanism, not a replacement for it, which is why we pair every prescription with the metabolic protocol and re-test both.
The honest approval status
Here is the part most content in this category blurs, and we will not. No GLP-1 is FDA-approved specifically for prediabetes. Wegovy and Zepbound are approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, a frame prediabetic patients frequently fit. Ozempic and Mounjaro are approved for type 2 diabetes, and Zepbound and Mounjaro are the same molecule, tirzepatide: cash-pay patients are routed to Zepbound, and Mounjaro fits insurance-covered type 2 diabetes care. A clinician treating a prediabetic patient with a GLP-1 is prescribing inside one of those approved frames, based on weight and metabolic criteria, which is standard and defensible practice. What no credible clinician does is call it an approved prediabetes treatment, because it is not.
Only branded, FDA-approved products are ever prescribed in our protocols: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo (orforglipron). Never compounded GLP-1, under any circumstance, and the compounded-versus-branded question is settled for us by the same logic that governs the rest of this page: prescribe what has been tested, at the dose on the label, with a clinician accountable for the result.
The options and their honest frames
What each is actually approved for
| Medication | FDA-approved use | Relevance in prediabetes |
|---|---|---|
| Wegovy / Wegovy Tablets | Chronic weight management, obesity or overweight with weight-related conditions | The most common frame for a prediabetic patient whose driver is weight |
| Zepbound | Chronic weight management and obstructive sleep apnea | Cash-pay tirzepatide; strongest weight-loss data in the class |
| Ozempic | Type 2 diabetes | Not the frame for pure prediabetes; relevant once diabetes is established |
| Mounjaro | Type 2 diabetes | Insurance-covered route for established diabetes, same molecule as Zepbound |
| Foundayo (orforglipron) | Oral GLP-1 | An oral option inside the weight-management frame |
Who is a candidate, and who is not
The candidacy decision in our protocols runs through the panel, and the logic is transparent. A patient with confirmed prediabetes, elevated fasting insulin, and overweight or obesity whose lifestyle execution is already underway is the textbook candidate: the medication amplifies the plan. A patient whose metabolic picture is mild and whose insulin markers are near normal may be better served by ninety days of protocol-only work and a re-test, because the medication's side effect burden and cost buy less at the margin. A patient whose glucose picture reflects something else entirely, thyroid dysfunction, high cortisol, a medication effect, needs that cause treated instead.
What disqualifies the conversation: personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis in some contexts, pregnancy or plans for it, and a patient who wants the prescription without the protocol. That last one is not a moral objection; it is an efficacy one. Medication without the metabolic plan produces less result, and the trial data everyone cites was generated with lifestyle structure in the background.
How the prescribing decision works here
The sequence is the same for every patient, and it is the sequence the fee structure protects. The clinical intake and the first comprehensive Biomarker Audit establish the baseline: HbA1c and fasting insulin for the glucose lane, ApoB and Lp(a) and hs-CRP for the cardiovascular and inflammatory lanes, full hormone and thyroid panels because they all read each other. The protocol names the mechanism and the markers expected to move. If a GLP-1 is indicated, it is introduced at the lowest effective dose, because the goal is the least medicine that gets the most result, and the titration conversation is about holding the lowest dose that works, not climbing on schedule. At ninety days the audit repeats, and the comparison decides whether to hold, taper or adjust.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network, and additional labs beyond the quarterly cadence are billed at pass-through cost.
Which of my labs made this the right call, and which one will tell us in ninety days whether it worked? If the answer is a number and a date, you are in a clinical relationship. If it is a dose and a refill, you are in a transaction.
What it costs, stated plainly
Membership is one flat $299 per month for the clinical layer: the quarterly Biomarker Audit, the clinician who reads it and answers between visits, and the written protocol. The first charge at checkout is $598, which is one charge covering the first two months together: the clinical intake, the first comprehensive panel, and the second month of care while your protocol is built. From month three it is $299 per month, month to month, and you can cancel anytime after the initial commitment.
The medicine is a separate charge, billed by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger, and in prediabetes that alignment has a concrete consequence: when your A1c normalizes and your insulin markers fall, tapering the medication is a success we look forward to, not a revenue line we mourn. If you are weighing a direct-pay membership against the system you are in now, finding a doctor for insulin resistance covers that comparison in full, and medical weight loss describes the prescribing program itself. If the fit sounds right, start with the eligibility assessment.
The objection we hear most
Are you just trying to sell me a drug for a condition I can reverse with diet and exercise? It is a fair challenge and the answer is no, and the trials prove it. The Diabetes Prevention Program showed lifestyle change alone cuts progression risk by 58 percent, and we build every prediabetes protocol on that foundation first. The medication question comes up when the labs show the compensation is already deep, or when a serious attempt at lifestyle structure has not moved the markers, and the trial evidence says medication on top of lifestyle beats either alone for many patients. We also reserve the right to tell you the opposite: a patient whose markers are mild gets ninety days of protocol-only work before any prescription is discussed, and the fee never changes with the answer, which is precisely why the answer can be no.
FAQ
Can a GLP-1 prevent type 2 diabetes in prediabetic patients? The trial evidence says the question is serious: post-hoc analysis of STEP 1 reported roughly 84 percent lower progression from prediabetes to type 2 diabetes over two years on semaglutide, and weight loss itself is a proven mechanism for restoring insulin sensitivity. It is a company-reported post-hoc figure, so we treat it as strong supporting evidence rather than settled fact.
Is a GLP-1 approved for prediabetes? No GLP-1 is FDA-approved specifically for prediabetes. Wegovy and Zepbound are approved for chronic weight management with weight-related conditions, and Ozempic and Mounjaro for type 2 diabetes; clinicians prescribing for prediabetic patients work within those approved frames.
Which GLP-1 is best for prediabetes? There is no head-to-head answer, and any confident one is marketing. Semaglutide and tirzepatide both produce major weight loss and glycemic improvement. The honest selection depends on your weight, your labs, your tolerability history and your clinician's protocol, not on a ranking.
Can prediabetes be reversed without medication? Often, yes. The Diabetes Prevention Program showed structured lifestyle change producing 5 to 10 percent weight loss cut progression risk by 58 percent, and insulin sensitivity measurably improves with resistance training and sleep repair. Medication is additive when the labs show it is needed, not a substitute for the protocol.
How much weight loss does it take to reverse prediabetes? Modest amounts move the needle: 5 to 10 percent of body weight measurably improves insulin sensitivity, and larger losses move it further. The trials that produced the strongest glycemic results were built on substantial, sustained weight loss, which is what the medication makes achievable for many patients.
How long would I stay on a GLP-1 for prediabetes? That is a labs question, not a calendar question. In our model the panel repeats every 90 days, and when A1c and insulin markers normalize and hold, a supervised taper is the plan, because the goal is the lowest effective dose or none.
Does insurance cover GLP-1s for prediabetes? Coverage follows the approved indications, so plans generally cover these medications for weight management with qualifying criteria or for type 2 diabetes, not for a prediabetes label. In our model the medication is billed by the pharmacy at pharmacy cost regardless, and the clinical fee is a flat $299 per month either way.
Related guides
- Cardiometabolic optimization: the definitive guide
- Doctor for insulin resistance: what to look for
- GLP-1 maintenance dose: the lowest effective dose
- Biomarker audits vs standard blood tests
- Medical weight loss at GoodLife Health
References
- Two-year effects of semaglutide in adults with overweight or obesity (STEP 1 extension, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/34591134/
- CDC: Prevent Type 2 Diabetes (Prediabetes overview). 2024. www.cdc.gov/diabetes/prevention-type-2/prediabetes-prevention.html
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/33567185/